Gujarat Kidney and Super Speciality Ltd
Financial results as on 31.03.2026
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 28 May 2026, 10:52 PM IST · BSE ID: 57ad5731-2213-4c3d-8d34-a908e58ba4b4
View Original BSE Filing (PDF)
💡
In Simple Terms
The hospital company reported its annual profit, saw its total assets grow significantly, but delayed hiring a new CEO.
🤖 AI Summary
- Audited Profit After Tax for FY2026 was Rs. 990.14 Lacs, compared to Rs. 910.90 Lacs in FY2025.
- Total Income for FY2026 stood at Rs. 4,059.47 Lacs, up from Rs. 3,528.11 Lacs in FY2025.
- Board of Directors deferred the appointment of a Chief Executive Officer (CEO).
- Company will conduct a postal ballot for shareholders to approve variation in IPO objects.
- Mr Siddharth Atulbhai Shah appointed Internal Auditor; SPANJ & Associates appointed Secretarial Auditor for five years.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Profit After Tax (Year Ended 31 March 2026)
990.14 Lacs
8.70%
Total Income (Year Ended 31 March 2026)
4,059.47 Lacs
15.06%
Total Assets (As at 31 March 2026)
26,607.67 Lacs
442.27%
Current Borrowings (As at 31 March 2026)
1,296.20 Lacs
1256.76%
Investments (As at 31 March 2026)
10,857.85 Lacs
7090.49%
🏢 How This Affects the Company
The deferral of a CEO appointment may indicate ongoing leadership transitions or strategic evaluation regarding the top executive role. The variation in IPO objects could imply shifts in planned business utilization of IPO funds or expansion strategies.
Total Assets increased to Rs. 26,607.67 Lacs as of March 31, 2026, from Rs. 4,907.22 Lacs as of March 31, 2025. Current borrowings increased to Rs. 1,296.20 Lacs from Rs. 95.53 Lacs over the same period, while investments rose significantly to Rs. 10,857.85 Lacs from Rs. 151.45 Lacs.
The appointment of new Internal and Secretarial Auditors establishes oversight for the financial year 2026-27, enhancing internal control and compliance frameworks. There is no immediate operational impact from the deferral of the CEO appointment.
Deferring the CEO appointment could introduce uncertainty regarding strategic direction or execution in the interim. A postal ballot for varying IPO objects indicates a potential change in previously communicated plans, which investors will monitor.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to participate in the postal ballot for approving the variation in objects of the IPO, once initiated.
👤
Who Is Affected
All shareholders will be affected by the proposed variation in IPO objects, as this could change the company's strategic use of capital. The deferral of CEO appointment affects all shareholders indirectly by extending leadership uncertainty.
🔍
Management Signal
The decision to defer the CEO appointment indicates management is either still evaluating candidates or internal alignment on the role, while the postal ballot signals a strategic review of previously stated IPO fund utilization.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of the postal ballot regarding variation in IPO objects.
Announcement of a new date for the CEO appointment by the Board.
Detailed disclosures on the utilization of significantly increased investments.
MEDIUM RISK
Deferred CEO appointment and plans to vary IPO objects introduce leadership and strategic uncertainty.
💡 Investor Takeaway
Gujarat Kidney and Superspeciality Ltd recorded an audited Profit After Tax of Rs. 990.14 Lacs for the year ended March 31, 2026, a 8.70% increase from Rs. 910.90 Lacs in FY2025. Total Assets surged to Rs. 26,607.67 Lacs from Rs. 4,907.22 Lacs. The Board deferred CEO appointment and approved a postal ballot for varying IPO objects.
⚖️ Strengths & Concerns
✅ Positives
- Profit After Tax for FY2026 increased to Rs. 990.14 Lacs, compared to Rs. 910.90 Lacs in FY2025.
- Total Assets grew significantly to Rs. 26,607.67 Lacs as of March 31, 2026, from Rs. 4,907.22 Lacs a year prior.
⚠️ Concerns
- Current financial liabilities from borrowings increased substantially to Rs. 1,296.20 Lacs as of March 31, 2026, from Rs. 95.53 Lacs.
- The appointment of a CEO was deferred by the Board, indicating a potential delay in leadership finalization.
📅 Company Track Record
Gujarat Kidney and Superspeciality Ltd reported an audited FY26 Profit After Tax of Rs. 990.14 Lacs, following a previous announcement on March 28, 2026, stating the same figure. A prior Q2 filing mentioned a profit up 69.5% YoY to Rs. 389.98 Lacs, but also noted a surge in short-term debt of 1,229% to Rs. 1,270.71 Lacs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Gujarat Kidney and Superspeciality Ltd's Profit After Tax for FY2026?
Gujarat Kidney and Superspeciality Ltd reported an audited Profit After Tax of Rs. 990.14 Lacs for the year ended March 31, 2026. This is an 8.70% increase compared to Rs. 910.90 Lacs in FY2025.
What were the Total Assets for Gujarat Kidney and Superspeciality Ltd as of March 31, 2026?
As of March 31, 2026, Gujarat Kidney and Superspeciality Ltd's Total Assets were Rs. 26,607.67 Lacs, a substantial increase from Rs. 4,907.22 Lacs as of March 31, 2025.
Was a CEO appointed at Gujarat Kidney and Superspeciality Ltd?
No, the Board of Directors of Gujarat Kidney and Superspeciality Ltd deferred the appointment of a Chief Executive Officer (CEO) at their meeting on May 28, 2026.
What action will Gujarat Kidney and Superspeciality Ltd take regarding its IPO objects?
Gujarat Kidney and Superspeciality Ltd will conduct a postal ballot to seek shareholder approval by way of a Special Resolution for Variation in Objects of its IPO.
Who was appointed as the Internal Auditor for Gujarat Kidney and Superspeciality Ltd?
Mr Siddharth Atulbhai Shah was appointed as the Internal Auditor for Gujarat Kidney and Superspeciality Ltd for the Financial Year 2026-27, effective May 28, 2026.
Questions based on this BSE filing only. For information purposes.